Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H19N5O |
Molecular Weight | 321.377 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1CCC(CC1)Oc2c(C#N)ncc3c2c4cccnc4[nH]3
InChI
InChIKey=XEZLBMHDUXSICI-UHFFFAOYSA-N
InChI=1S/C18H19N5O/c1-2-23-8-5-12(6-9-23)24-17-14(10-19)21-11-15-16(17)13-4-3-7-20-18(13)22-15/h3-4,7,11-12H,2,5-6,8-9H2,1H3,(H,20,22)
Molecular Formula | C18H19N5O |
Molecular Weight | 321.377 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 00:15:56 UTC 2021
by
admin
on
Sat Jun 26 00:15:56 UTC 2021
|
Record UNII |
4N173XZ7SX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4N173XZ7SX
Created by
admin on Sat Jun 26 00:15:56 UTC 2021 , Edited by admin on Sat Jun 26 00:15:56 UTC 2021
|
PRIMARY | |||
|
58266779
Created by
admin on Sat Jun 26 00:15:56 UTC 2021 , Edited by admin on Sat Jun 26 00:15:56 UTC 2021
|
PRIMARY | |||
|
DB14791
Created by
admin on Sat Jun 26 00:15:56 UTC 2021 , Edited by admin on Sat Jun 26 00:15:56 UTC 2021
|
PRIMARY | |||
|
1627539-18-7
Created by
admin on Sat Jun 26 00:15:56 UTC 2021 , Edited by admin on Sat Jun 26 00:15:56 UTC 2021
|
PRIMARY | |||
|
CHEMBL3545007
Created by
admin on Sat Jun 26 00:15:56 UTC 2021 , Edited by admin on Sat Jun 26 00:15:56 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> INHIBITOR |
Conclusions: It is safe and feasible to administer GDC-0425 with a standard dose of gem. At the doses assessed, bone marrow suppression is common but manageable and exposures exceed those predicted by preclinical models to inhibit Chk1. Clinical activity was observed, including 1 patient with TP53 mutated TNBC.
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |